Search This Blog

Friday, April 20, 2018

A REVIEW OF CYPASS AND XEN STENTS

From Review of Optometry:

"Unlike the CyPass, the Xen 45 gel stent (Allergan) mimics the outflow pattern of traditional glaucoma procedures by draining aqueous into the subconjunctival space, but with the less invasive ab interno approach. This stent is indicated as a stand-alone procedure or with cataract surgery for patients with open-angle, pseudoexfoliative or pigmentary glaucoma who failed maximum topical therapy or other filtering procedures. The Xen, preloaded in a single-use injector, is inserted through the trabecular meshwork, creating a scleral channel through which the stent connects the anterior chamber to the subconjunctival space. A clinical trial of 65 patients demonstrated a drop in IOP from a mean of 25.1mm Hg preoperatively to 15.1mm Hg postoperatively, with a reduction in medications from 3.5 before the procedure to 1.7 after.3 "

Thursday, April 19, 2018

CORNEA CROSS-LINKING RE-TREATMENT

According to a review of a study in Cornea:

“Parents of the younger patients must be clearly informed at the time of corneal cross-linking therapy (CXL) that seven to 10 years after CXL, the corneal collagen turnover may induce loss of CXL effect duration with new KC instability or progression, so the treatment could be potentially repeated if necessary in nearly 25% of the patients,”

Thursday, April 12, 2018

EYE DROPS FOR PRESBYOPIA

This article in Review of Optometry discusses development of eye drops for presbyopia in the near future. 

Tuesday, April 10, 2018

LINK BETWEEN VITAMIN D DEFICIENCY AND UVEITIS

According to this study:  "in patients with normal vitamin D levels were 21% less likely to have noninfectious uveitis than those with low vitamin D levels."

Tuesday, May 30, 2017

EYEDROPS IN PLACE OF AVASTIN IN WET MACULAR DEGENERATION

University of Birmingham develops revolutionary eye drops to treat age-related blindness
University of Birmingham Medical News

The results of collaborative research, published in the journal Investigative Ophthalmology and Visual Science, could spell the end of painful injections for age–related macular degeneration (AMD).

Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Aging, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.

BIOMARKER PREDICTS VISION LOSS

Washington University School of Medicine in St. Louis News

Research in mice and patients suggests biomarker could predict vision loss.

Studying mouse models of glaucoma, Ban, Apte and their colleagues identified a molecule in the eye called growth differentiation factor 15 (GDF15), noting that the levels of the molecule increased as the animals aged and developed optic nerve damage.

"comparing the fluid from patients without glaucoma to those with glaucoma, the GDF15 biomarker was significantly elevated in the glaucoma patients,” Apte said. “We also found that higher levels of the molecule were associated with worse functional outcomes, so this biomarker seems to correlate with disease severity.”

Apte and Ban don’t believe that the molecule causes cells in the retina to die; rather, that it is a marker of stress in retinal cells.

VITAMIN K1 REDUCES RISK OF CATARACTS

(HealthDay)—High intake of vitamin K1 is associated with reduced risk of cataracts, according to a study published online May 11 in JAMA Ophthalmology.
"High intake of dietary vitamin K1 was associated with a  of cataracts in an elderly Mediterranean population even after adjusting by other potential confounders," the authors write.

LATANOPROST AND MYOPIC PROGRESSION

It has been shown that form deprivation stimulates axial length growth and hence myopia.  In a study presented at the annual meeting of ARVO, young guinea pigs undergoing form deprivation were administered either daily latanoprost or daily vehicle for 12 weeks.  Those that received vehicle had a .18 mm axial length increase vs. a .01mm axial length increase in the latanoprost group.  This suggests there may be a possibility that daily topical latanoprost may help stop progression of myopia, offering a potential new treatment for the condition. 

Pain reliever may help relieve the vision damage of glaucoma


Medical College of Georgia at Augusta University News
Researchers want to know if the powerful pain medicine (+)–pentazocine can help avoid the damage from glaucoma. 
Their focus is astrocytes that normally nourish and protect retinal ganglion cells, at the juncture where the optic nerve sends visual information to the brain so we can see. Glaucoma appears to change the relationship between these two brain cell types so that astrocytes move from supportive to destructive mode.
“The theory is that in glaucoma, astrocytes (which normally nourish and protect the retina), become toxic to neurons,” said Dr. Kathryn Bollinger, glaucoma specialist at the Medical College of Georgia at Augusta University.
The research team has evidence that treatment with (+)–pentazocine calms the astrocytes, prompting them to release brain–derived neurotrophic factor, known to promote healthy survival of neurons.

Thursday, May 04, 2017

NEUROSTIMULATOR FOR DRY EYE

According the the American Academy of Ophthalmology:

The FDA approved TrueTear, an intranasal tear neurostimulator device designed to temporarily increase tear production in adult patients.

The handheld stimulator comes with daily disposable tips that are inserted into the nasal cavity for an effective, non–invasive and drug–free way to induce the production of tears.

Heart Pill for CSR

Researchers are leading a groundbreaking study into whether or not a drug used to treat heart failure, eplerenone, could save the sight of patients with recalcitrant central serous chorioretinopathy. 

Thursday, December 01, 2016

VITAMIN D AND DRY EYE

According to this study in Acta Ophthalmologica:

Vitamin D status may be an important factor for dry eye syndrome.

Wednesday, November 30, 2016

TOO MUCH LUTEIN?

This article from the University of Utah discusses how excess lutein supplementation in addition to dietary intake of lutein from greens can lead to crystalline deposits in the macula.  Authors recommend only qualified patients with risk for macular degeneration consider lutein supplementation.


Thursday, November 10, 2016

OCT AND MULTIPLE SCLEROSIS

This article in Review of Optometry discusses a link between multiple sclerosis and ganglion cell thinning.

Wednesday, October 26, 2016

CORNEAL CROSS-LINKING SAFE AND EFFECTIVE IN TEENS WITH KERATOCONUS

 This study reported in the Journal of Cornea and External Disease reports that corneal cross-linking is safe and effective at halting the progression of keratoconus in teen patients.